Arq, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARQ research report →
Range $7.5 – $7.5
Price Chart
About the company
Operating throughout North America, Arq, Inc. is a specialized manufacturer of activated carbon materials. Their product range encompasses various types of activated carbon, specifically granular, powdered, and colloidal forms.
- CEO
- Robert E. Rasmus
- IPO
- 2004
- Employees
- 202
- HQ
- Greenwood Village, CO, US
Get TickerSpark's AI analysis on ARQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $124.61M
- P/E
- -2.39
- Fwd P/E
- 47.38
- PEG
- 0.00
- P/S
- 0.98
- P/B
- 0.69
- EV/EBITDA
- -3.94
- Div Yield
- 0.00%
- Gross Margin
- 32.08%
- Op Margin
- -3.49%
- Net Margin
- -38.79%
- ROE
- -29.06%
- ROIC
- -2.27%
Latest fiscal year · YoY change
- Revenue
- $120.34M+10.4%
- Gross Profit
- $33.53M-15.0%
- Op Income
- $-8,106,000
- Net Income
- $-52,610,000-929.8%
- EPS
- $-1.27-807.1%
- OCF Growth
- -123.7%
- FCF Growth
- +85.2%
- 52W High
- $4.02
- 52W Low
- $1.54
- 50D MA
- $2.15
- 200D MA
- $2.41
- Beta
- 2.87
- RSI (14)
- 68
- Avg Volume
- 488.64K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arq delivered a record third quarter, raised the low end of 2026 adjusted EBITDA guidance, and said its PAC and PFAS initiatives are setting up additional growth into 2027.· November 5, 2026
- Q3 revenue hit a record $38.2 million, up about 9% year over year, with gross margin expanding to 39.7% from 28.8%.
- Adjusted EBITDA was $8.8 million versus $5.2 million a year ago, marking the 10th straight quarter of positive adjusted EBITDA.
- Management tightened full-year 2026 adjusted EBITDA guidance to $19 million-$20 million from $17 million-$20 million, while reiterating revenue guidance of $120 million-$125 million.
- PAC for PFAS testing is progressing with more than a dozen opportunities identified, and management expects revenue contribution in 2027, weighted to the back half.
- The company ended Q3 with $19.1 million of cash, including $7.8 million unrestricted, and total debt of $28.2 million.
- Management said 2027 could benefit from PAC for PFAS, cost savings, refinancing, operational improvements, and potential Corbin monetization.
Arq reported Q3 2026 revenue of $38.2 million, up from $35.1 million a year ago, with gross margin of 39.7% versus 28.8% in the prior-year period. Adjusted EBITDA was $8.8 million compared with $5.2 million last year, and net income was about $2.5 million versus a net loss of about $900,000 in Q3 2025. For full-year 2026, management tightened adjusted EBITDA guidance to $19 million-$20 million from $17 million-$20 million previously and reiterated revenue guidance of $120 million-$125 million. Capex guidance was reiterated at $8 million-$10 million.
Bob Rasmus emphasized that the foundational PAC business is performing well, with organic volume and pricing growth, improving margins, and record revenue. He framed the quarter as evidence that management is rebuilding investor credibility by meeting or beating targets, and he repeatedly pointed to a clearer path to higher profitability in 2027. His tone was confident but measured, especially on PFAS, where he said PAC for PFAS is the immediate priority because it can offer similar or better cash margins than GAC with little to no CapEx.
Shimon Steinmetz said the quarter was strong and ahead of expectations, driven primarily by higher seasonal PAC volume. He detailed the financials: revenue of $38.2 million, gross margin of 39.7%, adjusted EBITDA of $8.8 million, net income of $2.5 million, SG&A of $7.2 million, and R&D of about $800,000. He also said cash ended at $19.1 million, with $7.8 million unrestricted, unrestricted cash up nearly $7 million sequentially, and total debt down to $28.2 million, including $19.2 million drawn on the mid-cap facility.
Analysts focused on PAC for PFAS timing, testing, and commercialization, as well as whether 2027 growth depends on GAC. Management said there are more than a dozen testing opportunities, testing usually takes 1 to 3 months, and contract discussions are happening alongside testing; revenue is expected in 2027 and likely back-end loaded. On GAC, Rasmus said the timing decision is not dependent on PAC for PFAS adoption, but on return profile and acceptable funding. He also said any capacity constraints would be a 'pleasant problem,' and if needed the company would shift away from lower-margin volumes.
The call showed improving core PAC economics, with record revenue, strong margin expansion, and sustained positive adjusted EBITDA. Management believes PFAS remediation is a large and growing opportunity, and PAC for PFAS could generate meaningful 2027 revenue with minimal CapEx and potentially attractive pricing.
Management was clear that PAC for PFAS revenue is still early and likely back-end loaded in 2027, so near-term contribution appears limited. The company also still faces execution and funding decisions around GAC, and several 2027 upside items — refinancing, Corbin monetization, and efficiency gains — are not yet fully quantified or guaranteed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.8%
- Shares Outstanding
- 44.19M
- Float Shares
- 32.19M
Buy/sell ratio 25.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 35 ETFs
Biggest fund positions in ARQ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Steinmetz Shimon | buy | 1,098 |
| Sep 8, 26 | Steinmetz Shimon | buy | 1,874 |
| Sep 4, 26 | Steinmetz Shimon | buy | 1,402 |
| Sep 4, 26 | Steinmetz Shimon | buy | 4,356 |
| Sep 3, 26 | Steinmetz Shimon | buy | 7,500 |
| Sep 3, 26 | Steinmetz Shimon | buy | 8,770 |
| Sep 1, 26 | Owino Peter Oluoch | other | 61,047 |
| Sep 1, 26 | Owino Peter Oluoch | other | 100,000 |
| Sep 1, 26 | Owino Peter Oluoch | other | 61,047 |
| Aug 14, 26 | Wong Joseph M | other | 55,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARQ coverage
Recent articles, reports, and earnings notes.
No research on ARQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARQ report →Argo's September Oil Production
newsfilecorp.com · Nov 20
Water Tower Research Announces Inaugural WTR Forum Series Event, "CLEAN AIR AND WATER: Feedstock, Filtration, and PFAS Solutions," December 10, 2026
thenewswire.com · Nov 18
Arq: Plenty Of Upside After Best Quarter In Recent Years - Buy (Rating Upgrade)
seekingalpha.com · Nov 7
Arq, Inc. (ARQ) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
ARQ (NASDAQ:ARQ) versus Cabot (NYSE:CBT) Head-To-Head Survey
defenseworld.net · Nov 5
Arq, Inc. (ARQ) Tops Q3 Earnings and Revenue Estimates
zacks.com · Nov 4
Arq Reports Third Quarter 2026 Results
globenewswire.com · Nov 4
ARQ (ARQ) Projected to Release Earnings on Wednesday
defenseworld.net · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.